Form 4: Immunocore Holdings Director, Siddharth Kaul, Granted Share Options
SEC Form 4 Filing
Director Siddharth Kaul receives share options in Immunocore Holdings plc.
Summary
- Siddharth Kaul, a director of Immunocore Holdings plc, was granted share options on May 15, 2025.
- The options give Kaul the right to buy 26,198 ordinary shares at an exercise price of $29.06 per share.
- The options vest on the earlier of May 15, 2026, or the day before the next annual general meeting, contingent on continuous service.
- The options expire on May 14, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of share options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.
Positives
- The granting of share options aligns the director's interests with those of the shareholders, incentivizing performance and company growth.
Industry Context
Share-based compensation is a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the long-term success of the company. This is especially true for companies like Immunocore, which are focused on innovative therapies and require highly skilled personnel.
Comparison to Industry Standards
- Granting share options to directors is a standard practice in publicly traded companies, particularly in the biotech sector.
- Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their compensation packages for directors and executives.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the granting of share options positively as it aligns the director's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the transaction (grant of share options) |
| 05/15/2026 | Earliest vesting date for the share options |
| 05/14/2035 | Expiration date of the share options |
Keywords
Immunocore Holdings, Director, Share Options, Form 4, Beneficial Ownership, Kaul, IMCR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.